04:39 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Stabilizing the closed form of RyR2 for nephrotic syndrome

DISEASE CATEGORY: Renal INDICATION: Renal damage Preventing podocyte injury by stabilizing the closed form of the calcium channel RyR2 could treat nephrotic syndrome. Phosporylation of RyR2's serine at position 2808 (S2808) causes calcium leakage through...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET)

Ophthalmic disease INDICATION: Ophthalmic disease Mouse and fruit fly studies suggest MANF enhances the effectiveness of cell-based therapies for UV-damaged retinal tissue. In innate immune cells from Drosophila and mice, levels of MANF were higher...
07:00 , May 14, 2015 |  BC Innovations  |  Tools & Techniques

Actin up in schizophrenia

With the number of genetic risk factors linked to schizophrenia at over a hundred and counting, finding the right ones to follow is the field's next big challenge. A team at Duke University has simplified...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

MANF regulatory update

The European Commission granted Orphan Drug designation to MANF from Amarantus to treat retinitis pigmentosa (RP). The human growth factor that mediates apoptosis is in preclinical testing for the indication, for which it also has...
08:00 , Dec 11, 2014 |  BC Innovations  |  Targets & Mechanisms

Terazosin reborn

In searching for compounds to treat stroke or sepsis, a Chinese team has found a new activity-and possibly a new indication-for an old drug. Terazosin, a generic a-blocker used in hypertension, inhibited apoptosis and extended...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

University of Miami, Amarantus BioScience deal

Amarantus exercised its option to license exclusive, worldwide rights to IP from the university's Bascom Palmer Eye Institute covering the use of the mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET ) family of proteins to...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Amarantus BioScience, Washington University deal

Amarantus partnered with the Washington University School of Medicine to evaluate the efficacy of mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET ) in animal studies to treat Wolfram syndrome, a beta cell-degenerating disorder. The medical...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Amarantus BioScience, University of Massachusetts deal

Amarantus and the university entered an exclusive option agreement to license the university's method of use IP on the use of mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET )-family proteins for antibiotic-induced ototoxicity and other...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Amarantus BioScience, UMMS deal

On Dec. 18, 2013, the medical school granted Amarantus an exclusive, worldwide license to IP covering the use of mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET ) as a biomarker and as a treatment for...